|Bid||5.43 x 500|
|Ask||6.50 x 1000|
|Day's range||5.58 - 5.77|
|52-week range||3.95 - 9.25|
|PE ratio (TTM)||N/A|
|Earnings date||26 Feb 2018 - 2 Mar 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||8.50|
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that it has advanced a program exploring activin receptor-like kinase-2 (ALK2) inhibitors for treatment of Fibrodysplasia Ossificans Progressiva (FOP). Investigational New Drug Application (IND) enabling nonclinical development of optimized lead candidates BCX9250 and BCX9499 has been initiated with the goal of progressing to Phase 1 clinical trials in the first half of 2019. FOP is a very rare disease that affects approximately 1 in 2 million people worldwide.
RESEARCH TRIANGLE PARK, N.C., Jan. 03, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that executives from the Company are scheduled to provide a corporate summary and update regarding the Company’s clinical programs at the 36th annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 10, 2018 at 3:30 p.m. Pacific Time. Links to a live audio webcast and replay of the presentation may be accessed on the BioCryst website events page at http://investor.shareholder.com/biocryst/events.cfm.
On a per-share basis, the Durham, North Carolina-based company said it had a loss of 18 cents. The results fell short of Wall Street expectations. The average estimate of six analysts surveyed by Zacks ...